METHOD FOR MONITORING THE EFFECTIVENESS OF ANTIBIOTIC THERAPY IN THE TREATMENT OF ACUTE PYELONEPHRITIS IN INFANTS Russian patent published in 2021 - IPC G01N33/564 G01N33/70 G01N33/493 G01N33/573 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatrics and pediatric nephrology, and can be used to monitor the effectiveness of antibiotic therapy in the treatment of acute pyelonephritis in infants. A portion of urine is collected in a volume of 5 ml after the toilet of the genitals, before starting antibiotic therapy, with the determination in the urine of the initial level of Lipocalin-2 associated with neutrophilic gelatinase (uNGAL), and its standardization by conversion to mg of creatinine (uNGAL/Cr) in this portions of urine, with its repeated determination on the 2nd day of antibiotic therapy. If the uNGAL/Cr level decreases by 50% or less from the uNGAL/Cr level established before the start of antibiotic therapy, it is considered ineffective and a decision is made to change the antibiotic. In the case of a decrease of more than 50% from the initial level, continue the course of treatment with the same antibacterial drug until the uNGAL/Cr level decreases to 2.0 ng/mg or lower.

EFFECT: method provides an opportunity to obtain reliable information about the dynamics of the course of acute pyelonephritis in infants against the background of ongoing antibiotic therapy due to the implementation of a non-invasive method of monitoring the effectiveness of antibiotic therapy, which consists in determining in the urine the initial level of Lipocalin-2 associated with uNGAL before starting antibiotic therapy and 2- e day, and comparison of indicators, which provides an earlier accurate assessment of the effectiveness of antibiotic therapy and, in case of ineffectiveness, an early change of an ineffective antibacterial drug.

1 cl, 1 dwg, 1 tbl, 2 ex